{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:54:17Z","timestamp":1761746057117,"version":"3.37.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Foshan Science and Technology Innovation Project","award":["2320001006278"],"award-info":[{"award-number":["2320001006278"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13666-3","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T06:49:26Z","timestamp":1739342966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Experimental study of iodine-131 labeling of a novel tumor-targeting peptide, TFMP-Y4, in the treatment of hepatocellular carcinoma with internal irradiation"],"prefix":"10.1186","volume":"25","author":[{"given":"Juan","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyi","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiongying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongsheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuanming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"13666_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"key":"13666_CR2","doi-asserted-by":"publisher","first-page":"e1477459","DOI":"10.1080\/2162402X.2018.1477459","volume":"7","author":"CJ Wu","year":"2018","unstructured":"Wu CJ, Tsai YT, Lee IJ, et al. Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment. Oncoimmunology. 2018;7:e1477459. https:\/\/doi.org\/10.1080\/2162402X.2018.1477459.","journal-title":"Oncoimmunology"},{"key":"13666_CR3","doi-asserted-by":"publisher","unstructured":"Marwaha G, Macklis R, Singh AD, et al. Brachytherapy Dev Ophthalmol. 2013;52:29\u201335. https:\/\/doi.org\/10.1159\/000351053.","DOI":"10.1159\/000351053"},{"key":"13666_CR4","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1016\/j.bmc.2014.09.006","volume":"22","author":"J Sasaki","year":"2014","unstructured":"Sasaki J, Sano K, Hagimori M, et al. Synthesis and in vitro evaluation of radioiodinated indolequinones targeting NAD(P)H: quinone oxidoreductase 1 for internal radiation therapy. Bioorg Med Chem. 2014;22:6039\u201346. https:\/\/doi.org\/10.1016\/j.bmc.2014.09.006.","journal-title":"Bioorg Med Chem"},{"key":"13666_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nrclinonc.2012.203","volume":"10","author":"J Thariat","year":"2013","unstructured":"Thariat J, Hannoun-Levi JM, Sun Myint A, et al. Past, present, and future of radiotherapy for the benefit of patients. Nat Rev Clin Oncol. 2013;10:52\u201360. https:\/\/doi.org\/10.1038\/nrclinonc.2012.203.","journal-title":"Nat Rev Clin Oncol"},{"key":"13666_CR6","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1051\/medsci\/2019206","volume":"35","author":"J Barbet","year":"2019","unstructured":"Barbet J, Le Gouill S, Pelegrin A. [Radioimmunotherapy: the reasons for confidential clinical use and hope for development]. Med Sci (Paris). 2019;35:1062\u20135. https:\/\/doi.org\/10.1051\/medsci\/2019206.","journal-title":"Med Sci (Paris)"},{"key":"13666_CR7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1874471011666180502104524","volume":"11","author":"A Morgenstern","year":"2018","unstructured":"Morgenstern A, Apostolidis C, Kratochwil C, et al. An overview of targeted alpha therapy with (225)actinium and (213)Bismuth. Curr Radiopharm. 2018;11:200\u20138. https:\/\/doi.org\/10.2174\/1874471011666180502104524.","journal-title":"Curr Radiopharm"},{"key":"13666_CR8","doi-asserted-by":"publisher","unstructured":"Song G, Cheng L, Chao Y, et al. Emerging nanotechnology and Advanced materials for Cancer Radiation Therapy. Adv Mater. 2017;29. https:\/\/doi.org\/10.1002\/adma.201700996.","DOI":"10.1002\/adma.201700996"},{"key":"13666_CR9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3389\/fcell.2020.00676","volume":"8","author":"G Ni","year":"2020","unstructured":"Ni G, Chen S, Chen M, et al. Host-defense peptides caerin 1.1 and 1.9 stimulate TNF-Alpha-dependent apoptotic signals in human cervical Cancer HeLa cells. Front Cell Dev Biol. 2020;8:676. https:\/\/doi.org\/10.3389\/fcell.2020.00676.","journal-title":"Front Cell Dev Biol"},{"key":"13666_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1967\/s002449910803","volume":"21","author":"J Yuan","year":"2018","unstructured":"Yuan J, You X, Ni G, et al. Iodine-125 labeled Australian frog tree host-defense peptides caerin 1.1 and 1.9 better inhibit human breast cancer cells growth than the unlabeled peptides. (125)I-caerin 1.9 may better be used for the treatment of breast cancer. Hell J Nucl Med. 2018;21:115\u201320. https:\/\/doi.org\/10.1967\/s002449910803.","journal-title":"Hell J Nucl Med"},{"key":"13666_CR11","doi-asserted-by":"publisher","first-page":"114891","DOI":"10.1016\/j.biopha.2023.114891","volume":"164","author":"T He","year":"2023","unstructured":"He T, Du J, Zhu K, et al. Experimental study of (131)I-caerin 1.1 and (131)I-c(RGD)(2) for internal radiation therapy of esophageal cancer xenografts. Biomed Pharmacother. 2023;164:114891. https:\/\/doi.org\/10.1016\/j.biopha.2023.114891.","journal-title":"Biomed Pharmacother"},{"key":"13666_CR12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s12149-021-01618-3","volume":"35","author":"R Lin","year":"2021","unstructured":"Lin R, Ma B, Liu N, et al. Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice. Ann Nucl Med. 2021;35:811\u201322. https:\/\/doi.org\/10.1007\/s12149-021-01618-3.","journal-title":"Ann Nucl Med"},{"key":"13666_CR13","doi-asserted-by":"publisher","unstructured":"Liu N, He T, Xiao Z, et al. 131I-Caerin 1.1 and 131I-Caerin 1.9 for the treatment of non-small-cell lung cancer. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.861206.","DOI":"10.3389\/fonc.2022.861206"},{"key":"13666_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/s0969-8043(02)00192-6","volume":"57","author":"RE Weiner","year":"2002","unstructured":"Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot. 2002;57:749\u201363. https:\/\/doi.org\/10.1016\/s0969-8043(02)00192-6.","journal-title":"Appl Radiat Isot"},{"key":"13666_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1967\/s002449912003","volume":"23","author":"YY Zhou","year":"2020","unstructured":"Zhou YY, Zhang PP, Lin RT, et al. Investigating the theragnostic potential of (131)I-caerin peptide in thyroid cancer. Hell J Nucl Med. 2020;23:27\u201333. https:\/\/doi.org\/10.1967\/s002449912003.","journal-title":"Hell J Nucl Med"},{"key":"13666_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.peptides.2012.06.017","volume":"37","author":"JH Bowie","year":"2012","unstructured":"Bowie JH, Separovic F, Tyler MJ. Host-defense peptides of Australian anurans. Part 2. Structure, activity, mechanism of action, and evolutionary significance. Peptides. 2012;37:174\u201388. https:\/\/doi.org\/10.1016\/j.peptides.2012.06.017.","journal-title":"Peptides"},{"key":"13666_CR17","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1007\/s10620-019-05582-x","volume":"64","author":"S Saffo","year":"2019","unstructured":"Saffo S, Taddei TH. Systemic Management for Advanced Hepatocellular Carcinoma: a review of the Molecular pathways of Carcinogenesis, current and emerging therapies, and Novel Treatment Strategies. Dig Dis Sci. 2019;64:1016\u201329. https:\/\/doi.org\/10.1007\/s10620-019-05582-x.","journal-title":"Dig Dis Sci"},{"key":"13666_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/s0739-5930(09)79296-7","volume":"2009","author":"D Harnois","year":"2009","unstructured":"Harnois D. Sorafenib in Advanced Hepatocellular Carcinoma. Yearbook Gastroenterol. 2009;2009:218\u20139. https:\/\/doi.org\/10.1016\/s0739-5930(09)79296-7.","journal-title":"Yearbook Gastroenterol"},{"key":"13666_CR19","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389:2492\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(17)31046-2.","journal-title":"Lancet"},{"key":"13666_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000367758","volume":"4","author":"M Kudo","year":"2015","unstructured":"Kudo M. Immune Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer. 2015;4:201\u20137. https:\/\/doi.org\/10.1159\/000367758.","journal-title":"Liver Cancer"},{"key":"13666_CR21","doi-asserted-by":"publisher","unstructured":"Wang Z, Li J, Ji Y, et al. Traditional herbal medicine: a review of potential of inhibitory hepatocellular carcinoma in basic research and clinical trial. Evid Based Complement Alternat Med. 2013;2013(268963). https:\/\/doi.org\/10.1155\/2013\/268963.","DOI":"10.1155\/2013\/268963"},{"key":"13666_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/wjnm.WJNM_107_18","volume":"18","author":"B Hertz","year":"2019","unstructured":"Hertz B. A tribute to Dr. Saul Hertz: the discovery of the medical uses of radioiodine. World J Nucl Med. 2019;18:8\u201312. https:\/\/doi.org\/10.4103\/wjnm.WJNM_107_18.","journal-title":"World J Nucl Med"},{"key":"13666_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/1471-2407-14-114","volume":"14","author":"J Chen","year":"2014","unstructured":"Chen J, Zhu S, Tong L, et al. Superparamagnetic iron oxide nanoparticles mediated (131)I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice. BMC Cancer. 2014;14:114. https:\/\/doi.org\/10.1186\/1471-2407-14-114.","journal-title":"BMC Cancer"},{"key":"13666_CR24","doi-asserted-by":"publisher","first-page":"19798","DOI":"10.1021\/acsami.5b05836","volume":"7","author":"L Zhao","year":"2015","unstructured":"Zhao L, Zhu J, Cheng Y, et al. Chlorotoxin-conjugated multifunctional dendrimers labeled with Radionuclide 131I for single Photon Emission computed Tomography Imaging and Radiotherapy of Gliomas. ACS Appl Mater Interfaces. 2015;7:19798\u2013808. https:\/\/doi.org\/10.1021\/acsami.5b05836.","journal-title":"ACS Appl Mater Interfaces"},{"key":"13666_CR25","doi-asserted-by":"publisher","unstructured":"Yang X, Liu X, Li J, et al. Caerin 1.1\/1.9 enhances Antitumour immunity by activating the IFN-alpha response signalling pathway of Tumour Macrophages. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14235785.","DOI":"10.3390\/cancers14235785"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13666-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13666-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13666-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T15:27:01Z","timestamp":1739460421000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13666-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13666"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13666-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal research report was approved by The Animal Experiment Ethics Committee of the First Affiliated Hospital of Guangdong Pharmaceutical University. (Ethics approval number: FAHGPU20160316).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"245"}}